Abstract: Conventional ways of reducing pressure in the eye have inherent drawbacks and one such way to reduce these drawbacks is to provide an ocular drainage implant including a pliable plate which is so sized and shaped as to enable it to be positioned on a sclera surface or a sub-scleral space of an eye comprising a first exterior face and a second exterior face, with a plurality of apertures extending between the first and second faces, and a fluid drainage tube retaining structure; and a valve-less fluid drainage tube connected to the retaining structure and providing the implant with a longitudinal axis, the valve-less fluid drainage tube being adapted to drain fluid from an anterior chamber of the eye to the subconjunctival or the suprachoroidal space, wherein the retaining structure extends substantially across an entire dimension of the plate.

Abstract: A probe as disclosed herein is capable of treating both the Schlemm's canal (SC) and the trabecular meshwork (TM), or both the pars plicata and the iris root site of the eye, with electromagnetic radiation (e.g., laser light) to improve aqueous humor outflow and thus decrease intraocular pressure (IOP). The laser probe can include a tip capable of being placed on an eye, such as on a corneal limbus or a scleral limbal area of the eye. The tip can include an optical waveguide angled to direct laser light through both the SC and TM, or both the pars plicata and the iris root site of the eye. The laser light can be continuous or pulsed, and can be configured to provide appropriate therapy to both the SC and TM, or to both the pars plicata and the iris root site. The laser probe can facilitate performing trans-scleral trabeculoplasty treatment, especially trans-scleral Schlemm trabeculoplasty, and performing iridoplasty treatment.

Abstract: Provided herein are polymer microparticle-based compositions for the treatment of ocular diseases/disorders (e.g., glaucoma) and other diseases/disorders. Microparticle suspension formulations and solid polymer formulations are described, which provide extended ocular residence time and controlled release of therapeutic agents such as latanoprost, atropine, brimonidine, timolol, brinzolamide, dorzolamide, octyl methoxycinnamate (OMC) and benzophenone-3 (BP3). In specific embodiments, a topical composition comprising drug loaded poly(lactic-co-glycolic acid (PLGA) microparticles or chitosan-coated drug-loaded PLGA microparticles is prepared.